Clinical Trials

Inclusion Criteria:

All patients with MBL/CLL seen at Mayo Clinic, Rochester, MN will be considered for participation in this study.

• All patients who consent to participate will be assigned to one of five arms of the study:
  • Arm A: previously untreated MBL or CLL Rai stage 0;
  • Arm B: previously untreated CLL Rai Stage I-IV;
  • Arm C: CLL patients who are currently receiving therapy with single-agent ibrutinib;
  • Arm D: Patients who have undergone an allogeneic stem cell transplant, regardless of the indication for transplant;
  • Arm E: CLL patients who are currently receiving therapy with single-agent Acalabrutinib.

Exclusion Criteria:

Patients who meet any of the following exclusion criteria will not be registered to this study:

• Patients who have received Shingrix previously.
• Patients receiving therapy with other BTK inhibitors such as acalabrutinib, or other targeted agents such as venetoclax, etc.
• Patients receiving any other concomitant CLL directed therapy such as anti-CD20 monoclonal antibody (such as rituximab, ofatumumab or obinutuzumab).